Author Claim Review

 Quick Explanation Copied

 Long Explanation

Citation Metrics and Career Stage

OpenAlex records 37 works, 369 citations, and h-index 9 for Ana Carolina Guerta Salina (ORCID 0000-0003-3220-0413), with citations accelerating sharply since 2020 (18 in 2020 → 68 in 2024), driven largely by COVID-19-era work. Her most-cited first-author paper, on efferocytosis of SARS-CoV-2-infected cells in eLife (67 citations), and a co-authored JCI paper on C5aR1/NETs in COVID-19 (42 citations) anchor this rise. Earlier high-impact contributions include a first-author PNAS paper on leukotriene B4 licensing inflammasome activation (32 citations) and a co-authored PNAS paper on PGE2 during efferocytosis (41 citations). Topic weights confirm a coherent focus: inflammation (0.80), macrophages (0.72), immunology (0.71).

Figure 1. Citations received per year show a monotonic rise from 2020 onward; 2024–2026 totals exceed prior years despite fewer published works, indicating increasing impact per paper.

Scientific Identity and Trajectory

Her publication arc is unusually coherent: polymer physics detector papers (early career, pre-immunology), then photodynamic therapy for pneumonia, then a sustained program in macrophage–lipid mediator biology (PGE2, LTB4) during infection and efferocytosis, culminating in skin-resident macrophage work. The 2026 preprints exemplify this program: SB89, a clonal dermal-macrophage-like line (2,347 genes upregulated vs iBMDMs, defense/chemotaxis GO enrichment) was built and then deployed as the in vitro backbone for the hyperglycemia–Dectin-1 study SB89 characterization and RNA-seq data. This tool-then-application pairing is a hallmark of strong experimentalists.

Evidence Quality in the Two Flagship Preprints

The hyperglycemia paper triangulates across levels: in vivo lesion data (diabetic 72 ± 0.55 mm² vs control 62 ± 0.55 mm², p < 0.0001, though n = 7 vs 4 is small), transcriptomics (1,585 up/963 downregulated genes under high glucose), phospho-kinase arrays, genetic (Dectin-1 KO) and pharmacologic (laminarin, PF-03549184) perturbations, human keratinocytes, and a BioVU PheWAS (~240,000 individuals; CLEC7A rs16910633 OR 1.93 for dermatomycosis) In vivo, in vitro, and PheWAS evidence. BGPT assessment: this is strong mechanistic triangulation, but both papers are preprints (not yet peer-reviewed), in vivo cohorts are small, STZ diabetes models type-1-like hyperglycemia, laminarin has off-target effects, and data-availability statements are absent — all acknowledged limitations that should temper confidence pending independent replication.

Blindspots and Uncertainties

Known unknowns: (1) citation counts differ between databases (285 vs 369), reflecting coverage gaps typical for junior researchers; (2) no primary_institution listed in OpenAlex despite USP/UNESP affiliations on papers — author disambiguation is imperfect; (3) whether SB89's transcriptional fidelity persists across passages is untested; (4) the PheWAS odds ratios are observational and confounded by dysmetabolism. None of these undermine the core program, but peer review and independent validation remain outstanding for the 2026 claims.

 BGPT Author Review

Scientific Quality

First-author PNAS and eLife papers, an h-index of 9 with an accelerating citation trajectory (68 in 2024), and coherent mechanistic programs (efferocytosis, lipid mediators, skin macrophages) indicate a strong experimental immunologist. Weaknesses: modest absolute citation mass, reliance on immortalized cell-line models, small in vivo cohorts, and the flagship 2026 work is not yet peer-reviewed.

Communication Quality

Papers show structured, multi-panel mechanistic storytelling and clear one-sentence summaries; open-access publication is frequent (gold OA on key papers). Deductions: some titles are dense/technical, and data-availability statements are missing from both 2026 preprints, limiting transparency.

Author Novelty

The SB89 dermis-imprinted cell line and the 'maladaptive Dectin-1 under hyperglycemia' reframe of a canonical receptor are genuinely new contributions; efferocytosis-impairs-immunity work was established earlier by her group/mentors, so novelty is incremental-plus rather than paradigm-shifting.

Scientific Rigor

Triangulation across genetics, pharmacology, transcriptomics, and human genetics (PheWAS) is rigorous; proper statistical thresholds (BH-adjusted p < 0.05) are used. Rigor gaps: n = 4–7 in vivo groups, no data availability statements, laminarin specificity concerns, and 25 mM glucose may not mirror tissue microenvironments.